RFA-AT-24-001: Research Network to Promote Multidisciplinary Mechanistic and Translational Studies of Sickle Cell Disease Pain (U24, Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $600,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 1, 2023.
From the official notice on Grants.gov, last changed February 28, 2023. Checked November 7, 2026.
- Award ceiling$600,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU24
- Clinical trialsOptional
- Funded byNCCIH
- Median yearly award$929,890
- Typical project length5 years
- U24, Resource-Related Research Project Cooperative Agreement. Shared research resources such as data centers or coordinating centers, with substantial NIH involvement. Other open U24 notices.
Projects funded under RFA-AT-24-001 were run by National Center for Complementary and Integrative Health (NCCIH, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AT-24-001 in the NIH Guide.
Key dates
| Posted | February 27, 2023 |
|---|---|
| Deadline | October 1, 2023 |
| Archived by Grants.gov | November 6, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $929,890; it allows up to $600,000 per award.
- Most of the program's money (71% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this FOA is to support a Research Network that promotes multidisciplinary mechanistic and translational studies of Sickle Cell Disease (SCD) pain. This network is expected to develop compelling research frameworks and model systems that will support interdisciplinary collaborations; initiate pilot projects to test novel mechanistic hypotheses in the high-priority research areas listed below and develop novel technologies and methodologies to study pain in the organ(s) typically impacted by SCD. To accomplish these objectives, applicants can propose activities such as meetings, workshops, conferences, research collaborations, exchange of ideas through visiting scientist arrangements, or training opportunities. These activities will help identify unique research gaps and opportunities that can be addressed through the network in the form of pilot projects which will in turn generate the preliminary data needed for SCD pain investigators to successfully compete for more substantial NIH grants, including The Helping to End Addiction Long-term (HEAL) Initiative grant awards. In addition, the network shall sustain its scientific impact through a variety of dissemination and outreach strategies, including publication of research frameworks, reviews, and other best practices to foster the growth and development of research in priority areas.
Funded under RFA-AT-24-001 so far
NIH funded 1 project under RFA-AT-24-001 in fiscal 2024 to 2026, at 1 institution. The median yearly award was $929,890.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Sickle Cell Disease Pain Analgesia And Integrative Network | University of California-Irvine | 2026 | $924,408 |
Who has won Research and Training in Complementary and Integrative Health grants before
From fiscal 2021 to 2025, Research and Training in Complementary and Integrative Health (93.213) awarded $575 million across 653 grant awards, an average of $880,790 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 15 | $25.9 million |
| The General Hospital Corporation | Massachusetts | 23 | $23.1 million |
| Duke University | North Carolina | 11 | $20.0 million |
| The Regents of the University of California, San Francisco | California | 16 | $15.2 million |
| Regents of the University of Minnesota | Minnesota | 13 | $15.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AT-24-001 still open?
No. It closed on October 1, 2023.
Who can apply for Research Network to Promote Multidisciplinary Mechanistic and Translational Studies of Sickle Cell Disease Pain (U24, Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Research Network to Promote Multidisciplinary Mechanistic and Translational Studies of Sickle Cell Disease Pain (U24, Clinical Trial Optional)?
Closed October 1, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $600,000 each.
Who has been funded under RFA-AT-24-001?
NIH RePORTER lists 1 project funded under RFA-AT-24-001 in fiscal 2024 to 2026, at 1 institution.
Who has won Research and Training in Complementary and Integrative Health grants before?
The largest recipients over five fiscal years were Yale Univ, The General Hospital Corporation, Duke University. The program made 653 awards worth $575 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Microplastics Research and Resource Coordination Center (U24 - Clinical Trial Not Allowed)
- IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)
- Network of the National Library of Medicine Training Center (U24 Clinical Trial Not Allowed)
- Network of the National Library of Medicine Coordinating Center (U24 Clinical Trial Optional)